Tag Archives: adc research

26Oct/18

The Success of Seattle Genetics/Wutian ADC Adcetris for Phase III Clinical Surgery of Peripheral T Cell Lymphoma (PTCL)

October 03, 2018 – Seattle Genetics and Takeda recently announced the evaluation of antibody conjugates Adcetris (brentuximab vedotin) for the treatment of peripheral T-cell lymphoma (PTCL, also known as mature Phase IIIRead More…

15Jun/18

Forward I Phase III Trial of Mirvetuximab Sorvtansine in Platinum-resistant Ovarian Cancer Completes Full Enrollment

The FORWARD I Phase III registration trial (NCT02631876) evaluating the antibody-drug conjugate or ADC mirvetuximab soravtansine as a single-agent therapy for the treatment of platinum-resistant ovarian cancer, has completed full enrollment andRead More…